Ovarian Cancer Drugs Market Scope And Analysis

  • Report Code : TIPRE00003750
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Ovarian Cancer Drugs Market Analysis, Trends, and Scope 2021 to 2022

Buy Now

Ovarian Cancer Drugs Market Report Ovarian Cancer Drugs Market Size and Share Ovarian Cancer Drugs Market Scope and Analysis

Ovarian Cancer Drugs Market Report Scope

Report Attribute Details
Market size in 2022 US$ 2.1 Billion
Market Size by 2030 US$ 3.8 Billion
Global CAGR (2022 - 2030) 7.7%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Type
  • Epithelial Ovarian Cancer
  • Germ Cell Ovarian Cancer
  • Stromal Tumors
By Drug Class
  • PARP Inhibitors
  • Anti-Angiogenesis Inhibitors
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Elli Lilly
  • AstraZeneca
  • GSK
  • Zielab
  • ImmunoGen
  • GeneTech Roche
  • Vivesto
  • Allarity Therapeutics Inc
  • Aeterna Zentaris

    • Industry Developments and Future Opportunities:

    The ovarian cancer drugs market forecast can help stakeholders in this marketplace plan their growth strategies. A few strategic developments by leading players operating in the market are listed below:

    • In November 2022, ImmunoGen won FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients resistant to platinum-resistant epithelial ovarian cancer. The ELAHERE is specifically approved for patients with FRα-positive platinum-resistant ovarian cancer, which is a challenging condition due to the availability of limited treatment options and poor clinical outcomes of the existing therapeutics.

    Competitive Landscape and Key Companies:

    Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are among the prominent companies profiled in the ovarian cancer drugs market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.